BCL2 and myeloid neoplasm: In addition, myeloid neoplasms with erythroid differentiation was proved to be more resistant to venetoclax owing to their diminished reliance on the antiapoptotic protein BCL2 (69), a finding that aligns synergistically with our observations showing normal erythroid cells were G2-featured, associated with higher sensitivity to venetoclax.